Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTUMN Phase 2a study of ALXN1920 in primary membranous nephropathy
2025-520780-40-00Phase 2Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in idiopathic membranous glomerulonephritis (IMG) comparing ALXN1920 with Placebo (2 arms). Primary endpoint: Change from baseline in proteinuria based on 24-hour UPCR. Planned start Nov 2025; status: authorised.
02
Drugs
ALXN-1920
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2025-520780-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520780-40-00.